medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 1

<< Back Next >>

Ann Hepatol 2013; 12 (1)

Therapeutic effects of granulocyte-colony stimulating factor on non-alcoholic hepatic steatosis in the rat

Yi-Sun S, Cheng-Hu F, Byung-Im S, Jun-Young P, Dae Won J, Kyung-Soo K

Language: English
References: 42
Page: 115-122
PDF size: 248.63 Kb.


ABSTRACT

Background and rationale. Non-alcoholic hepatic steatosis refers to the accumulation of triglycerides in the liver in the absence of alcohol consumption. Granulocyte colony-stimulating factor (G-CSF) has been reported to be an effective treatment for a variety of liver diseases. We examined the possible therapeutic effects of G-CSF on non-alcoholic hepatic steatosis in rats. Material and methods. Thirty-week-old Otsuka Long Evans Tokushima Fatty (OLETF) rats received water containing 30% sucrose for 8 weeks to promote the development of non-alcoholic hepatic steatosis. After development of the model, the rats were injected with G-CSF (100 µ g/kg/day) or saline for 5 days. Four weeks after this treatment, serum levels of glucose, total cholesterol (TC), triglyceride (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and free fatty acids (FFA) were measured. Histology was examined by hematoxylin and eosin (H-E) and periodic acid Schiff (PAS) staining, and levels of expression of hepatic lipogenic enzymes were determined by RT-PCR. Results. The G-CSF-treated rats displayed significantly fewer lipid droplets than the saline-treated rats (P ‹ 0.01), and their levels of sterol regulatory element-binding protein (SREBP)-1c, fatty acid synthase (FAS), and acetyl-CoA carboxylase (ACC) mRNAs were also lower (P ‹ 0.01), as were their liver weight and serum levels of TG and FFA (P ‹ 0.05). Conclusion. Our results indicate that G-CSF ameliorated non-alcoholic hepatic steatosis in the OLETF rat, and this therapeutic effect involved a reduction of SREBP-1c expression. Therefore, G-CSF deserves further study as a potential treatment for non-alcoholic hepatic steatosis.


REFERENCES

  1. Day CP, James OF. Hepatic steatosis: innocent bystander or guilty party? Hepatology 1998; 27: 1463-6.

  2. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007; 45: 1366-74.

  3. Alba LM, Lindor K. Review article: Non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2003; 17: 977-86.

  4. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006; 368: 1681-8.

  5. Oliveira CP, Faintuch J, Rascovski A, Furuya CK Jr., Bastos Mdo S, Matsuda M, Della Nina BI, et al. Lipid peroxidation in bariatric candidates with nonalcoholic fatty liver disease (NAFLD)-preliminary findings. Obes Surg 2005; 15: 502-5.

  6. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-52.

  7. Vizzutti F, Arena U, Nobili V, Tarquini R, Trappoliere M, Laffi G, Marra F, et al. Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease. Ann Hepatol 2009; 8: 89-94.

  8. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 2008; 14: 185-92.

  9. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513-7.

  10. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.

  11. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114: 842-5.

  12. Postic C, Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 2008; 34: 643-8.

  13. Zohlnhofer D, Ott I, Mehilli J, Schomig K, Michalk F, Ibrahim T, Meisetschlager G, et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 2006; 295: 1003-10.

  14. Sato T, Suzuki H, Kusuyama T, Omori Y, Soda T, Tsunoda F, Shoji M, et al. G-CSF after myocardial infarction accelerates angiogenesis and reduces fibrosis in swine. Int J Cardiol 2008; 127: 166-73.

  15. Jin SZ, Meng XW, Sun X, Han MZ, Liu BR, Wang XH, Sun LY, et al. Granulocyte colony-stimulating factor enhances bone marrow mononuclear cell homing to the liver in a mouse model of acute hepatic injury. Dig Dis Sci 2010; 55: 2805-13.

  16. Fang B, Luo S, Song Y, Li N, Li H, Zhao RC. Intermittent dosing of G-CSF to ameliorate carbon tetrachloride-induced liver fibrosis in mice. Toxicology 2010; 270: 43-8.

  17. Lim YH, Joe JH, Jang KS, Song YS, So BI, Fang CH, Shin J, et al. Effects of granulocyte-colony stimulating factor (GCSF) on diabetic cardiomyopathy in Otsuka Long-Evans Tokushima Fatty rats. Cardiovasc Diabetol 2011; 10: 92.

  18. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010; 8: e1000412.

  19. Schroeder M, Zagoory-Sharon O, Shbiro L, Marco A, Hyun J, Moran TH, Bi S, et al. Development of obesity in the Otsuka Long-Evans Tokushima Fatty rat. Am J Physiol Regul Integr Comp Physiol 2009; 297: R1749-R1760.

  20. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992; 41: 1422-8.

  21. Rector RS, Uptergrove GM, Morris EM, Borengasser SJ, Laughlin MH, Booth FW, Thyfault JP, et al. Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model. Am J Physiol Gastrointest Liver Physiol 2011; 300: G874-G883.

  22. Yeon JE, Choi KM, Baik SH, Kim KO, Lim HJ, Park KH, Kim JY, et al. Reduced expression of peroxisome proliferatoractivated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2004; 19: 799-804.

  23. Rector RS, Thyfault JP, Morris RT, Laye MJ, Borengasser SJ, Booth FW, Ibdah JA. Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats. Am J Physiol Gastrointest Liver Physiol 2008; 294: G619-G626.

  24. Rector RS, Thyfault JP, Laye MJ, Morris RT, Borengasser SJ, Uptergrove GM, Chakravarthy MV, et al. Cessation of daily exercise dramatically alters precursors of hepatic steatosis in Otsuka Long-Evans Tokushima Fatty (OLETF) rats. J Physiol 2008; 586: 4241-9.

  25. Chiu CC, Chen KP, Liu HC, Lu ML. The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. J Clin Psychopharmacol 2006; 26: 504-7.

  26. Ferno J, Vik-Mo AO, Jassim G, Havik B, Berge K, Skrede S, Gudbrandsen OA, et al. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology (Berl) 2009; 203: 73-84.

  27. Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Okuda M, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002; 122: 352-65.

  28. Ji Y, Dahmen U, Madrahimov N, Madrahimova F, Xing W, Dirsch O. G-CSF administration in a small-for-size liver model. J Invest Surg 2009; 22: 167-77.

  29. Guo Z, Bu S, Yu Y, Ghatnekar G, Wang M, Chen L, Bu M, et al. Diazoxide prevents abdominal adiposity and fatty liver in obese OLETF rats at prediabetic stage. J Diabetes Complications 2008; 22: 46-55.

  30. Narayan KA, McMullen JJ, Butler DP, Wakefield T, Calhoun WK. Effect of exercise on tissue lipids and serum lipoproteins of rats fed two levels of fat. J Nutr 1975; 105: 581-7.

  31. Gauthier MS, Couturier K, Latour JG, Lavoie JM. Concurrent exercise prevents high-fat-diet-induced macrovesicular hepatic steatosis. J Appl Physiol 2003; 94: 2127-34.

  32. Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, et al. Effect of granulocyte colonystimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 318: 1414-22.

  33. Ferre P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 2010; 12(Suppl. 2): 83-92.

  34. Kim YW, Kim YM, Yang YM, Kim TH, Hwang SJ, Lee JR, Kim SC, et al. Inhibition of SREBP-1c-mediated hepatic steatosis and oxidative stress by sauchinone, an AMPK-activating lignan in Saururus chinensis. Free Radic Biol Med 2010; 48: 567-78.

  35. Sekiya M, Yahagi N, Matsuzaka T, Najima Y, Nakakuki M, Nagai R, Ishibashi S, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003; 38: 1529-39.

  36. Sozio MS, Liangpunsakul S, Crabb D. The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis. Semin Liver Dis 2010; 30: 378-90.

  37. Dentin R, Pegorier JP, Benhamed F, Foufelle F, Ferre P, Fauveau V, Magnuson MA, et al. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem 2004; 279: 20314-26.

  38. Zhang YL, Hernandez-Ono A, Siri P, Weisberg S, Conlon D, Graham MJ, Crooke RM, et al. Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J Biol Chem 2006; 281: 37603-15.

  39. Oliveira CP, Gayotto LC, Tatai C, Della Nina BI, Lima ES, Abdalla DS, Lopasso FP, et al. Vitamin C and vitamin E in prevention of Nonalcoholic Fatty Liver Disease (NAFLD) in choline deficient diet fed rats. Nutr J 2003; 2: 9.

  40. idela LA, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med 2006; 12: 555-8.

  41. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1135-G1139.

  42. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, Goldstein JL. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci USA 1999; 96: 13656-61.




2020     |     www.medigraphic.com